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ABSTRACT
Sphingosine-1-phosphate (S1P) is a bioactive lipid involved in cell signaling
and, if released from cells, also plays a crucial role in regulating the trafficking of
lympho-hematopoietic cells, including primitive hematopoietic stem/progenitor cells
(HSPCs). It has been demonstrated that S1P chemoattracts HSPCs, and its level in
peripheral blood creates a gradient directing egress of these cells during mobilization.
In this paper we analyzed hematopoiesis in mice deficient in sphingosine kinase 2
(Sphk2-KO mice) and studied the effect of this mutation on plasma S1P levels. We
found that Sphk2-KO mice have normal hematopoiesis, and, in contrast to Sphk1KO mice, the circulating S1P level is highly elevated in these animals and correlates
with the fact that HSPCs in Sphk2-KO animals, also in contrast to Sphk1-KO animals,
show enhanced mobilization. These results were recapitulated in wild type (WT)
animals employing an Sphk2 inhibitor. We also administered an inhibitor of the S1Pdegrading enzyme S1P lyase, known as tetrahydroxybutylimidazole (THI), to WT
mice and observed that this resulted in an increase in S1P level in PB and enhanced
mobilization of HSPCs. In sum, our results support a crucial role for S1P gradients in
blood plasma in the mobilization process and indicate that small-molecule inhibitors
of Sphk2 and Sgpl1 could be employed as mobilization-facilitating compounds. At
the same time, further studies are needed to explain the unexpected effect of Sphk2
inhibition on increasing S1P levels in plasma.

INTRODUCTION

phenomenon of homing to BM of cells circulating in PB
[7]. S1P is highly expressed in tissue fluids, such as blood
and lymph, and in PB its most important sources are red
blood cells, albumin, and apoM bound to high-density
lipoproteins (HDL) [8]. The high concentration of S1P in
PB creates an important chemotactic gradient across the
endothelium between BM and PB [2].
As a bioactive lipid and a phosphorylated product
of sphingosine, S1P is an important intracellular second
messenger and, if released from the cells, is a ligand

Evidence has accumulated that the bioactive
lipid sphingosine-1-phosphate (S1P) is an important
chemoattractant for lymphocytes [1, 2] and, together
with ceramide-1-phosphate (C1P), plays a pivotal role
in the trafficking of hematopoietic stem/progenitor
cells (HSPCs) [2, 3]. S1P has been reported to play a
role both in mobilization of HSPCs from bone marrow
(BM) into peripheral blood (PB) [4–6] and in the reverse
www.impactjournals.com/oncotarget
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for five different G protein-coupled S1P receptors
(S1P1-5) [2, 9]. Of these receptors, S1P receptor type 1
(S1P1) and (as recently demonstrated) S1P3 [2, 10–12]
play an important role in the trafficking of lympho/
hematopoietic cells. An important source of sphingosine is
ceramide, and sphingosine is derived from ceramides in a
ceramidase-dependent manner. The process of sphingosine
phosphorylation to produce S1P is governed by
sphingosine kinases. Two forms of sphingosine kinase —
type 1 (Sphk1) and type 2 (Sphk2)—have been described
[2, 13, 14]. Sphk1 is found in the cytosol of eukaryotic
cells and shifts to the plasma membrane upon activation,
while Sphk2 is localized to the cell nucleus [15]. As
previously demonstrated, mice with Sphk1 knockout are
poor HSPC mobilizers [5] and have impaired homing of
HSPCs after transplantation [16].
On the one hand, S1P can be inactivated by
dephosphorylation
with
sphingosine
phosphate
lyase (Sgpl1) [17]. Inhibition of Sgpl1 with
tetrahydroxybutylimidazole (THI), which is a smallmolecule inhibitor of this enzyme, results in an increase
in S1P levels in PB and leads to release of c-kit+ stem
cells from BM in a mouse model of acute myocardium
infarction [18]. On the other hand, Sgpl1 inhibition by THI
has been related to its immunosuppressive role as a result
of retention of lymphocytes in lymphoid organs, which
results in lymphopenia [19].
Recently published results suggest a crucial role of
the S1P level in PB in directing egress of HSPCs from
BM into PB [20, 21]. To better address this question we
performed mobilization studies in Sphk2-KO mice and
WT mice exposed to inhibitors of Sphk2 and Sgpl1 to
modulate the level of S1P in PB.
We show what is counterintuitive, that is, the S1P
level in Sphk2-KO mice and wild type (WT) mice exposed
to a small-molecule Sphk2 inhibitor is elevated relative to
control animals and Sphk1-KO animals. The S1P plasma
level was also increased in THI-treated animals. Moreover,
our mobilization experiments lend further support to there
being a crucial role of the S1P blood level in egress of
HSPCs from BM into PB, as enhanced mobilization in
Sphk2-deficient mice and WT mice exposed to Sphk2
and Sgpl1 inhibitors was correlated with an increased S1P
plasma level but not with significant changes in the level
of CXCL12 (stromal-derived factor 1; SDF-1).

Sphk2-KO animals. However, to our surprise, as shown
in Figure 1, we found that Sphk2-KO show enhanced
mobilization in response to a short (3-day) G-CSF-, a long
(6-day) G-CSF-, or Plerixafor-induced mobilization.
Supplementary Figure 1 shows that the Sphk2KO mice employed in our studies have normal PB
cell counts (Supplementary Figure 1A), red blood cell
parameters (Supplementary Figure 1B), numbers of bone
marrow-residing HSPCs (Supplementary Figure 1C), and
clonogenic progenitors (Supplementary Figure 1D) under
steady-state conditions compared with WT animals.

Changes in S1P and CXCL12 level in Sphk1-KO
and Sphk2-KO mice
Since the mobilization of HSPCs from BM into
PB correlates with the plasma level of S1P, we measured
the S1P level in WT, Sphk1-KO and Sphk2-KO animals.
Figure 2 shows that, in contrast to Sphk1-KO mice, the
plasma level of S1P is significantly elevated in Sphk2-KO
mice. Thus, the increase in S1P in the PB of Sphk2-mutant
animals suggests the mobilization-promoting gradient for
HSPCs. However, a molecular explanation of the increase
in S1P is not clear at this time and requires further study.
The S1P plasma level was also increased as expected in
THI-treated Sphk1-KO mice. Interestingly Sphk2-KO
mice, in contrast to Sphk1-KO and WT animals, also had
elevated levels of C1P in PB (Supplementary Figure 2),
which indicates that changes in S1P level in PB in Sphk2KO mice are echoed by changes in the level of another
chemotactic factor for HSPCs, C1P [2, 23].
We also evaluated CXCL12 levels in conditioned
media harvested from BM supernatants (Figure 2B) and
PB plasma (Figure 2C) harvested from WT, Sphk1-KO,
and Sphk2-KO mice mobilized for 6 days with G-CSF
(Figure 2B). While there were no major changes in
CXCL12 levels in the conditioned media and plasma of
G-CSF-mobilized animals, the baseline CXCL12 level
was enhanced in the plasma of Sphk1-KO mice. Of note,
this increase in CXCL12 level in PB plasma reached 1.5
ng/ml, which is still a very low concentration that, as we
previously demonstrated, is not alone sufficient to promote
migration of HSPCs [7, 20].

Inhibition of S1P lyase (Sgpl1) by
tetrahydroxybutylimidazole (THI) enhances the
S1P level in PB and enhances mobilization in WT
animals

RESULTS
Sphingosine kinase 2-deficient (Sphk2-KO) mice
show enhanced mobilization

Since Sgpl1 degrades S1P, we became interested
in whether inhibition of this enzyme would increase
mobilization of HSPCs in WT animals. We found that
inhibition of Sgpl1 did increase the S1P level in PB in
both WT [19, 20, 25] and Sphk1-KO animals (Figure 2A).
This increase in plasma S1P level was correlated with
enhanced mobilization in WT mice exposed to the Sgpl1

It has been reported that the mobilization of HSPCs
is impaired in sphingosine kinase 1-deficient (Sphk1-KO)
mice, due to a low plasma level of S1P [5, 22]. Since
Sphk2 is another enzyme involved in S1P synthesis, we
became interested in whether a similar effect occurs in
www.impactjournals.com/oncotarget
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In comparison with WT animals, Sphk2-KO
mice show defective BM engraftment of HSPCs

inhibitor THI. To support this Figure 3 shows enhanced
mobilization of HSPCs in WT animals pretreated with THI
in response to G-CSF and Plerixafor administration.

In our previous work we demonstrated that
S1P enhances CXCL12-mediated homing and even
compensates in case of any deficiency in homing to BM
of HSPCs infused into PB [26]. Based on our current
observation that the S1P plasma level is high in Sphk2-KO
animals, we asked whether this increase prevents homing
to BM of HSPCs. To address this question we performed
WT HSPC transplants in WT and Sphk2-KO animals.
We found that Sphk2-KO mice transplanted with
BMMNCs labeled with green immunofluorescence
protein (GFP) showed impaired homing of GFP+ BM
cells compared with WT mice 24 hours later (Figure
5A). Moreover, 12 days after transplantation Sphk2KO animals transplanted with GFP+ BMMNCs had
lower numbers of clonogenic CFU-GM colonies in BM

Inhibition of Sphk2 by small-molecule inhibitor
of SLM6041434 enhances the S1P level in PB
and enhances mobilization in WT animals
Moreover, corroborating our results shown in Figure
2A, it has been recently reported that the S1P level is
elevated in blood of WT mice exposed to a small-molecule
inhibitor of Sphk2, SLM6041434 [24]. Therefore, to
investigate whether WT mice exposed to SLM6041434
better mobilize HSPCs, we performed mobilization studies
in these animals. Figure 4 shows that WT mice exposed
to SLM6041434 better mobilized HSPCs in response to
G-CSF and Plerixafor than control animals not exposed to
this Sphk2 inhibitor.

Figure 1: Sphk2-KO mice show enhanced mobilization with G-CSF and Plerixafor. Mononuclear cells were isolated from
WT and SphK2-KO mice after 3 days (Panel A) or 6 days (Panel B) of G-CSF mobilization (100 μg/kg per day, subcutaneously) or after
Plerixafor-induced mobilization (5 mg/kg, intraperitoneal injection, Panel C). The numbers of WBCs, SKL (Sca-1+ c-kit+ Lin−) cells, HSCs
(Sca-1+ CD45+ Lin−), and CFU-GM clonogenic progenitors were evaluated from PB. Results from two separate experiments are pooled
together. *P ≤ 0.05.
www.impactjournals.com/oncotarget
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DISCUSSION

and lower numbers of CFU-S colonies than control
WT animals (Figure 5B). Finally, Sphk2-KO animals
transplanted with WT BMMNCs showed delayed recovery
of neutrophil and platelet counts compared with control
mice (Figure 6).

The seminal observation of this report is that Sphk2null mice and mice exposed to Sphk2 and Sgpl1 inhibitors
have elevated S1P levels in PB and show enhanced

Figure 2: Measurements of S1P and CXCL12 levels. Panel (A) Steady-state S1P plasma level in WT, Sphk1-KO, Sphk2-KO, and

Sphk1-KO mice exposed to THI. Panel (B) CXCL12 concentration in conditioned media from BM after 6 days of G-CSF mobilization in
Sphk1-KO and Sphk2-KO animals. Panel (C) Left: the plasma level of CXCL12 in Sphk1-KO and Sphk2-KO animals under steady-state
conditions. Right: the plasma level of CXCL12 in Sphk1-KO and Sphk2-KO animals mobilized for 6 days with G-CSF. Results from two
separate experiments are pooled together.
www.impactjournals.com/oncotarget
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Figure 3: Impact of an S1P lyase (Sgpl1) inhibitor on the mobilization of HSPCs. WT mice received mobilizing agents and
tetrahydroxybutylimidazole (THI) administered ad libitum in water or vehicle. Mononuclear cells were isolated after 3 days of G-CSF(Panel A) or Plerixafor-induced mobilization (Panel B). The numbers of WBCs, SKL (Sca-1+ c-kit+ Lin−) cells, HSCs (Sca-1+ CD45+ Lin−),
and CFU-GM clonogenic progenitors were evaluated in PB. Results from two separate experiments are pooled together. *P ≤ 0.05.

Figure 4: Impact of an Sphk2 inhibitor on the mobilization of HSPCs. WT mice received mobilizing agents and SLM6041434
compound (or instead of SLM6041434 compound, control mice received vehicle). Mononuclear cells were isolated after 3 days of G-CSF(Panel A) or Plerixafor-induced mobilization (Panel B). The numbers of WBCs, Sca-1+ c-kit+ Lin− cells (SKL cells), HSCs (Sca-1+ CD45+
Lin−), and CFU-GM clonogenic progenitors were evaluated in PB. Results from two separate experiments are pooled together. *P ≤ 0.05.
www.impactjournals.com/oncotarget

65592

Oncotarget

mobilization of HSPCs. Thus, our results support the
conclusion that S1P is a major PB chemoattractant for
HSPCs [2, 4, 5, 16, 20]. We also demonstrate that in the
reverse process of homing of HSPCs from PB into BM, an
elevated S1P level in PB, as seen in Sphk2-KO animals,
may impair hematopoietic cell homing and engraftment.
Overall, our results provide further support for the
presence of a “tug of war” between BM and PB mediated
by an S1P gradient that affects trafficking of HSPCs [27].
S1P has been proposed to play a role in trafficking
of lymphocytes [1, 2], and more recently this trafficking
has been found to include egress of hematopoietic
progenitor cells form BM into PB [4–6]. Specifically,
our group and others have demonstrated the pivotal
role of S1P in egress of both hematopoietic stem cells
and hematopoietic progenitors from BM into PB in
the process of pharmacological mobilization induced
by G-CSF or Plerixafor [5, 20]. We also proposed

the concept that the S1P level is already very high in
circulating PB under steady-state conditions, which
supports the notion that HSPCs are actively retained in
the BM microenvironment by the CXCL12–CXCR4 and
VCAM-1–VLA4 axes to prevent their egress into PB in
response to an S1P gradient [21, 28]. The S1P level in PB
may also increase during mobilization in response to the
release of this chemoattractant from red blood cells and
platelets in response to activation of the complement and
coagulation cascades [2, 20, 21]. Both of these cascades
are crucial in induction of mobilization processes in
response to pharmacology, inflammation, stress, or tissue
injury [6, 29–33].
Interestingly an increase in S1P level alone in
response to red blood cell hemolysis (for example,
induced by administration of phenylhydrazine (PHZ),
when neither complement nor coagulation cascades are
activated) does not significantly induce egress of HSPCs

Figure 5: Defects in homing and short-term engraftment of HSPCs in Sphk2-KO mice. Panel (A) Lethally irradiated

mice (six mice per group) were transplanted with 7 × 106 bone marrow mononuclear cells (BMMNCs) from B6-GFP+ mice. Twenty-four
hours after transplantation, femoral BMMNCs were harvested, the number of GFP+ cells was evaluated by FACS (Panel A, left), and
the clonogenic CFU-GM progenitors were enumerated in an in vitro colony assay (Panel A, right). No colonies were formed in lethally
irradiated and non-transplanted mice (irradiation control). Panel (B) Lethally irradiated mice (six per group) were transplanted with 2.5 × 105
BMMNCs from WT mice. Twelve days after transplantation, femoral BMMNCs were harvested to evaluate the number of CFU-GM
colonies in clonogeneic assays (Panel B, left), and the spleens were removed to enumerate the number of CFU-S colonies (Panel B, right).
The data represent the combined results from two independent experiments for each panel. *p < 0.005.
www.impactjournals.com/oncotarget
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into the circulation [21]. As reported, the doubling of
S1P level in PB from damaged erythrocytes in response
to PHZ-induced hemolysis only marginally increased the
number of HSPCs circulating in PB. However, if mice are
exposed to PHZ together with the CXCR4 blocking agent,
Plerixafor, a robust synergistic increase in the number of
mobilized HSPCs occurred [21]. This finding supports
the concept that HSPCs first have to be released from
BM niches by blocking the CXCL12–CXCR4 retention
signal in order to respond to the S1P gradient between
BM and PB. This is why induction of a proteolytic [34]
and lipolytic [35] microenvironment in BM initiated by
activation of the complement cascade[7, 8] is crucial to
attenuating the biological function of the retention axes
for HSPCs in BM and facilitates their egress into PB in
response to an S1P gradient [7, 8, 34, 35].
S1P is synthesized by phosphorylation of
sphingosine by the kinases Sphk1 and Sphk2 and is

degraded by Sgpl1 or S1P phosphatase or is extruded
by S1P transporters, such as sphingolipid transporter 2
(Spns2) [2, 13, 14, 17, 36]. Mice that are deficient in
both Sphk1 and Sphk2 die in utero with no detectable
S1P, which suggests an important role for S1P in
development [9]. However, single-knockout mice are
viable. Interestingly, while Sphk1-KO mice display a
decrease by ~50% of the S1P level circulating in PB
[37], mice with Sphk2 deficiency have a somewhat
unexpected 2–4-fold increase in S1P level in PB plasma
and whole blood [24, 38]. It has already been reported
that Sphk1-KO mice are poor mobilizers of HSPCs
[5], which nicely correlates with the low level of blood
plasma S1P in these animals [37]. Based on the fact that
Sphk2-KO mice have elevated levels of S1P in PB, we
performed mobilization studies in these animals and
demonstrated that, as expected, they show enhanced
mobilization after 3-day or 6-day administration of

Figure 6: Defects in engraftment of HSPCs in Sphk2-KO mice. Lethally irradiated WT and Sphk2-KO mice were transplanted
with 2 × 105 BMMNCs from WT cells. White blood cells (Panel A) and platelets (Panel B) were counted before irradiation and at intervals
5, 7, 11, 16, 21, and 28 days after irradiation. The data represent the combined results from two independent experiments for each panel.
*p < 0.005.
www.impactjournals.com/oncotarget
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G-CSF and after mobilization by employing the CXCR4
receptor antagonist Plerixafor.
This increase in S1P level in peripheral blood
in Sphk2-KO mice correlating with their enhanced
mobilization state was reproduced using a nontoxic dose
of the Sphk2 inhibitor SLM6041434. In our hands, WT
mice exposed to this compound better mobilized HSPCs
after either G-CSF or Plerixafor administration, and we
confirmed that this correlated with an increase in S1P
level in PB. We obtained additional support for the pivotal
role of an increase in S1P level in circulating blood in the
egress of HSPCs from BM by employing the commercially
available Sgpl1 inhibitor tetrahydroxybutylimidazole
(THI) [18, 19, 25]. WT mice exposed to this compound
again turned out to better mobilize HSPCs than control
animals not exposed to THI. This observation supports our
recent results performed in mice after experimental acute
myocardium infarction (AMI) in which administration of
THI led to an increase in S1P level in PB and mobilization
of c-kit+ stem cells from BM [18]. This enhanced
mobilization of stem cells resulted in an increase in
angiogenesis, improved recovery of cardiac functional
parameters, and reduction in scar size [18].
The increased baseline level of S1P in Sphk2-KO
mice is intriguing. As reported recently, mass-labeled S1P
is cleared more slowly in these mutant animals, which
suggests that Sphk2 deficiency results also in decreased
clearance of circulating S1P and strongly suggests that this
enzyme may have additional yet-unrecognized functions
independent of the intracellular synthesis of S1P [24].
Several explanations for this phenomenon have been
proposed [24], for example, a compensatory increase in
Sphk1 activity or a so-far-uncharacterized S1P-degrading
capacity as a lyase or phosphatase. However none of these
explanations is conclusive, and this phenomenon requires
further study.
A striking aspect of S1P biology is its
compartmentalization between tissues and circulating
fluids [24, 39, 40]. Specifically, S1P levels are, as
mentioned above, significantly higher in PB and lymph
than in tissues, for example, in the BM microenvironment
[8]. However, as we previously demonstrated, the
S1P level is upregulated in BM after conditioning for
hematopoietic transplant by radio- or chemotherapy [7].
This effect supports the presence of a dynamic tug of war
between the S1P gradient (between PB and BM) and the
retention axes. The important role of S1P in homing of
HSPCs, which functionally supports the CXCL12–CXCR4
homing axis, has been demonstrated after transplantation
of CXCR4-deficient HSPCs into Sphk1-KO animals [16].
In the current paper we support this tug-of-war concept
between the S1P gradient between BM and PB and the
retention axes and demonstrate that a high level of S1P
in PB, as seen in Sphk2-KO mice, impairs both homing
and short-term engraftment of HSPCs in lethally irradiated
WT mice.
www.impactjournals.com/oncotarget

Since a role for S1P has been proposed in the
trafficking of malignant hematopoietic cells, targeting
the S1P axis may also become an important part of antileukemic therapy [2]. The mechanism of Sphk2 inhibitors
in leukemia is mainly based on increasing autophagic
death, as seen for example in T cell-acute lymphocytic
leukemia [41, 42], or a decrease in cell proliferation and
induction of apoptosis in multiple myeloma cells [43]. Our
findings reported in this work show that there are most
likely clear differences in the Sphk2 requirement between
normal and malignant hematopoietic cells, as Sphk2
deficiency does not affect normal hematopoiesis in Sphk2KO mice, and we did not observe any negative effects of
an Sphk2 inhibitor on clonogenic proliferation of normal
HSPCs in the in vitro toxicity studies performed.
In conclusion, our novel results support the
overall concept that the S1P level in PB is a major
chemoattractant for BM-residing HSPCs and the presence
of a tug of war between BM and PB due, in part, to this
bioactive sphingolipid. Thus, changes in S1P gradient
direct mobilization of HSPCs and may affect BM homing
of these cells after transplantation. Moreover, drugs that
inhibit Sphk2 activity (e.g., SLM6041434) or inhibit
Sgpl1 (e.g., THI) could increase our armamentarium of
available HSPC-mobilizing drugs. Since it has also been
demonstrated that another bioactive sphingolipid, C1P,
also directs trafficking of HSPCs, and its level is elevated
in SphK2-KO animals, further studies are needed to
study the relationship between the synthesis of both
phosphosphingolipids.

MATERIALS AND METHODS
Animals
In our experiments we employed pathogen-free, 6- to
8-week-old C57BL/6J (WT), B6N.129S6-Sphk1tm1Rlp/J
(Sphk1-KO) and B6N.129S6-Sphk2tm1Rlp/J (Sphk2KO) female mice established by Rick Proia [13, 16] and
purchased from the Jackson Laboratory (Bar Harbor, ME,
USA) at least 2 weeks before the experiments. Animal
studies were approved by the Animal Care and Use
Committee of the University of Louisville (Louisville,
KY, USA).

Drug administration
For Sphk2 inhibition, mice were injected i.p. with
5 mg/kg SLM6031434 or an equal volume of vehicle
(2% solution of hydroxypropyl-β-cyclodextrin; Cargill
Cavitron 82004; Cargill Inc., Cedar Rapids, IA). To
inhibit S1P lyase, mice received vehicle or 25 mg/L
tetrahydroxybutylimidazole THI (Sigma-Aldrich, St.
Louis, MO) administered ad libitum in water containing
5% dextrose (to improve palatability). THI is a Food and
Drug Administration-approved caramel food coloring
65595
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additive shown to inhibit S1P lyase when administered
orally to mice [19, 25].

of WBCs plated = number of CFU-GM per μl of PB; and
(number of WBCs x number of SKL cells)/number of
gated WBCs = number of SKL cells per μl of PB [35, 44].

Murine bone marrow-derived mononuclear cells

PB parameter counts

Bone
marrow-derived
mononuclear
cells
(BMMNCs) were obtained by flushing femurs and tibias
of pathogen-free experimental mice. Cells were lysed with
BD Pharm Lyse buffer (BD Biosciences, San Jose, CA,
USA) to remove red blood cells, washed, and resuspended
in appropriate media for further analysis [35, 44].

To obtain leukocyte and RBC counts, 50 μl of PB
was taken from the retro-orbital plexus of the mice and
collected in microvette EDTA-coated tubes (Sarstedt Inc.,
Newton, NC, USA), and samples were analyzed within 2 h
of collection on a HemaVet 950 analyzer (Drew Scientific
Inc., Waterbury, CT, USA) [35, 44, 45].

Mobilization

Clonogenic in vitro assay

Experimental mice were injected subcutaneously
(s.c.) with 100 μg/kg G-CSF (Amgen, Thousand Oaks,
CA, USA) daily for 3 (short mobilization) or 6 (long
mobilization) days and one dose at 5 mg/kg (i.p.) of
Plerixafor (AMD3100) (Sigma-Aldrich). At 6 h after
the last G-CSF administration or at 1 h after Plerixafor
injection mice were bled from the retro-orbital plexus for
hematology analysis, and PB was obtained from the vena
cava with a 25-gauge needle and 1-ml syringe containing
50 μl of 100 mM ethylenediaminetetraacetic acid (EDTA;
Quality Biological Inc., Gaithersburg, MD, USA).
Mononuclear cells (MNCs) were obtained by hypotonic
lysis of RBCs in BD Pharm Lyse buffer [35, 44].

RBCs from PB or BM were lysed with BD Pharm
Lyse buffer. Nucleated cells were subsequently washed,
counted, and resuspended in human methylcellulose
base medium provided by the manufacturer (R&D
Systems, Minneapolis, MN, USA). To evaluate the
number of clonogenic progenitor cells, BMMNCs were
supplemented with erythropoietin (5 U/ml; Stemcell
Technologies, Vancouver, BC, Canada) plus stem cell
factor (SCF; 5 ng/ml; R&D Systems) and resuspended
in methylcellulose base medium (for determining the
number of burst-forming units-erythroid; BFU-E)(R&D
Systems). For determining the number of megakaryocytic
progenitors (CFU-Meg) BM-MNC were supplemented
with thrombopoietin (100 ng/ml; Gibco Thermo Fisher
Scientific, Waltham, MA, USA) plus mIL-3 (10 ng/ml;
ProSpec-Tany Technogene Ltd., East Brunswick, NJ,
USA), and resuspended in plasma clots. For determining
number of granulocyte/monocytic colonies (CFU-GM)
BM-MNC were supplemented with 25 ng/ml recombinant
murine granulocyte macrophage colony-stimulating factor
(mGM-CSF; Millipore, Billerica, MA, USA) and 10 ng/ml
recombinant murine interleukin 3 (mIL-3; Millipore) and
cultured in in methylcellulose base medium. Cultures were
incubated for 7 to 14 days (37°C, 95% humidity, and 5%
CO2), at which time they were counted under an inverted
microscope (Olympus CK40; Olympus, Shinjuku, Tokyo,
Japan) [16, 44, 45].

Fluorescence-activated cell sorting (FACS)
analysis
The following monoclonal antibodies were
used to perform staining of Lin−/Sca-1+/c-Kit+ (SKL)
cells and Lin−/Sca-1+/CD45+ hematopoietic stem cells
(HSCs): FITC–anti-CD117 (also known as c-Kit, clone
2B8; BioLegend, San Diego, CA, USA) and PE–Cy5–
anti-mouse Ly-6 A/E (also known as Sca-1, clone D7;
eBioscience, San Diego, CA, USA). All anti-mouse
lineage marker [5] antibodies, including anti-CD45R/
B220 (clone RA3-6B2), anti-Ter-119 (clone TER-119),
anti-CD11b (clone M1/70), anti-T cell receptor β (clone
H57-597), anti-Gr-1 (clone RB6-8C5), anti-TCRγδ (clone
GL3), and anti-CD45 (clone 30-F11), were purchased
from BD Biosciences and conjugated with PE as described
[35, 44]. Staining was performed in RPMI 1640 medium
containing 2% FBS. All monoclonal antibodies (mAbs)
were added at saturating concentrations, and the cells were
incubated for 30 min on ice, washed twice, and analyzed
with an LSR II flow cytometer (BD Biosciences).

Quantitation of S1P and C1P levels
PB samples were obtained from the retro-orbital
plexus of the mice into tubes containing 1:5 ratio of
EDTA:CTAD. Plasma was isolated by centrifuging
whole blood for 10 min at 700 g. Supernatant was then
removed and centrifuged at 10,000 g for 10 min to
remove platelets, and the supernatant was then used for
lipid measurements. Lipids were extracted from plasma,
supernatant using acidified organic solvents, as previously
described [46, 47]. An analysis of S1P and C1P was
carried out using a Shimadzu UFLC coupled with an AB
Sciex 4000-Qtrap hybrid linear ion trap triple quadrupole

Evaluation of HSPC mobilization
For evaluation of circulating colony-forming unitgranulocyte/macrophage (CFU-GM) and SKL cells, the
following formulas were used: (number of white blood
cells [WBCs]) x number of CFU-GM colonies)/number
www.impactjournals.com/oncotarget
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mass spectrometer in multiple reaction monitoring mode
as previously described [47]. The mobile phase consisted
of 75/25 of methanol/water with formic acid (0.5%)
and 5mM ammonium formate (0.1%) as solvent A and
99/1of methanol/water with formic acid (0.5%) and 5mM
ammonium formate (0.1%) as solvent B. The column was
equilibrated back to the initial conditions in 3min. The
flow rate was 0.5mL/min with a column temperature of
60°C. The sample injection volume was 10 μL. The mass
spectrometer was operated in the positive electrospray
ionization mode with optimal ion source settings
determined by synthetic standards with a declustering
potential of 46V, entrance potential of 10V, collision
energy of 19V, collision cell exit potential of 14V, curtain
gas of 30psi, ion spray voltage of 5,500V, ion source gas1/
gas2 of 40psi, and temperature of 550°C. for S1P, total
S1P (DH-S1P and S1P) is reported. For C1P, total C1P
which is the sum of all C1P species (C2-C1P, C12-C1P,
C-14 C1P, C16-C1P, DH-16 –C1P, C18-C1P, C18-1-C1P,
C20-C1P, C22-C1P, C24-C1P, C24-C1P, C24-1-C1P, C26C1P and C26-1-C1P) is reported.

of incubation (37°C, 95 % humidity, and 5 % CO2),
the number of colonies was scored under an inverted
microscope [16, 44, 45].

CXCL12 assessment following G-CSF and
Plerixafor therapy

Recovery of leukocytes and platelets

Evaluation of engraftment
For short-term engraftment experiments,
experimental mice were irradiated with 1000 cGy of
γ-irradiation. After 24 h, mice were transplanted by tail
vein injection with 2.5 × 105 BM cells from WT mice,
and the femora of the transplanted mice were flushed
with PBS on day 12 post-transplant. After purification
via Ficoll-Paque, BM cells were plated in serum-free
methylcellulose cultures and stimulated to grow CFUGM colonies with mGM-CSF (25 ng/ml) and IL-3
(10 ng/ml). After 7 days of incubation (37°C, 95 %
humidity, and 5 % CO2) the number of colonies was
scored under an inverted microscope. Spleens were also
removed, fixed in Telesyniczky’s solution for CFU-S
assays, and the colonies on the surface of the spleen
counted [16, 44, 45].

Experimental mice were lethally irradiated, and after
24 h the animals were transplanted by tail vein injection
with 2 × 105 BM cells from WT mice. Transplanted mice
were bled at various intervals from the retro-orbital plexus
to obtain samples for white blood cell and platelet counts.
Fifty microliters of PB was taken from the retro-orbital
plexus of the mice into EDTA-coated Microvette tubes
(Sarstedt Inc., Newton, NC, USA) and run within 2 h
of collection on a HemaVet 950FS hematology analyzer
(Drew Scientific Inc., Oxford, CT, USA) [16, 44, 45].

6-8-week-old sphingosine kinase 1 and 2 KO
mice as well as appropriate age- and sex-matched C57/
Bl6 WT control mice were used for these studies. Mice
were mobilized by subcutaneous injection of 100 μg/kg
human G-CSF (Amgen, Thousand Oaks, CA) daily for 6
days and a single intraperitoneal injection of Plerixafor
5 mg/kg (Sigma, St. Louis, MO) on the sixth day. Six
hours after the last G-CSF injection/2 h post Plerixafor
injection, peripheral blood (PB) [47] was obtained from
the vena cava (with a 25-gauge needle and 1-mL syringe
containing CTAD + EDTA). Plasma was obtained using
centrifugation of PB samples at 700g for 10 minutes.
Bone marrow (BM) supernatant was isolated from flushed
tibia and femur in identical volume (500 µl) of ice-cold
PBS. Supernatant was isolated following centrifugation at
700g for 10 minutes. CXCL12 ELISA (DY460 kit) was
performed in duplicate on plasma and BM supernatant
samples using manufacturer protocol (R&D Systems,
Minneapolis, MN, USA) [35].

Statistical analysis
All results are presented as mean ± SD. Statistical
analysis of the data was done using Student’s t-test for
unpaired samples (Excel, Microsoft Corp., Redmond,WA,
USA) with a value of p ≤ 0.05 considered significant.
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